Abstract
Summary
According to our LPI (LP Information) latest study, the global Neurological Biomarkers market size was valued at US$ 6786.1 million in 2023. With growing demand in downstream market, the Neurological Biomarkers is forecast to a readjusted size of US$ 15430 million by 2030 with a CAGR of 12.4% during review period.
The research report highlights the growth potential of the global Neurological Biomarkers market. Neurological Biomarkers are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurological Biomarkers. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurological Biomarkers market.
A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.
Global Neurological Biomarkers key players include Thermo Fisher Scientific, Merck, Quest Diagnostics, Abbott, etc. Global top four manufacturers hold a share about 25%.
North America is the largest market, with a share over 55%, followed by Europe, and Asia-Pacific, both have a share over 35 percent.
In terms of product, Proteomics is the largest segment, with a share about 30%. And in terms of application, the largest application is Proteomics, followed by Drug Discovery, Personalized Medicine, etc.
Key Features:
The report on Neurological Biomarkers market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurological Biomarkers market. It may include historical data, market segmentation by Type (e.g., Proteomics, Genomics), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurological Biomarkers market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurological Biomarkers market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurological Biomarkers industry. This include advancements in Neurological Biomarkers technology, Neurological Biomarkers new entrants, Neurological Biomarkers new investment, and other innovations that are shaping the future of Neurological Biomarkers.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurological Biomarkers market. It includes factors influencing customer ' purchasing decisions, preferences for Neurological Biomarkers product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurological Biomarkers market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurological Biomarkers market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurological Biomarkers market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurological Biomarkers industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurological Biomarkers market.
Market Segmentation:
Neurological Biomarkers market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Proteomics
Genomics
Imaging
Bioinformatics
Others
Segmentation by application
Diagnostics
Drug Discovery
Personalized Medicine
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
Merck
Quest Diagnostics
Abbott
Roche
Illumina
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Cisbio Bioassays
Athena Diagnostics
BGI
Wuxi APP
Aepodia
Proteome Sciences
Genewiz
Key Questions Addressed in this Report
What is the 10-year outlook for the global Neurological Biomarkers market?
What factors are driving Neurological Biomarkers market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurological Biomarkers market opportunities vary by end market size?
How does Neurological Biomarkers break out type, application?
The research report highlights the growth potential of the global Neurological Biomarkers market. Neurological Biomarkers are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurological Biomarkers. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurological Biomarkers market.
A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.
Global Neurological Biomarkers key players include Thermo Fisher Scientific, Merck, Quest Diagnostics, Abbott, etc. Global top four manufacturers hold a share about 25%.
North America is the largest market, with a share over 55%, followed by Europe, and Asia-Pacific, both have a share over 35 percent.
In terms of product, Proteomics is the largest segment, with a share about 30%. And in terms of application, the largest application is Proteomics, followed by Drug Discovery, Personalized Medicine, etc.
Key Features:
The report on Neurological Biomarkers market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurological Biomarkers market. It may include historical data, market segmentation by Type (e.g., Proteomics, Genomics), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurological Biomarkers market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurological Biomarkers market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurological Biomarkers industry. This include advancements in Neurological Biomarkers technology, Neurological Biomarkers new entrants, Neurological Biomarkers new investment, and other innovations that are shaping the future of Neurological Biomarkers.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurological Biomarkers market. It includes factors influencing customer ' purchasing decisions, preferences for Neurological Biomarkers product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurological Biomarkers market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurological Biomarkers market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurological Biomarkers market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurological Biomarkers industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurological Biomarkers market.
Market Segmentation:
Neurological Biomarkers market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Proteomics
Genomics
Imaging
Bioinformatics
Others
Segmentation by application
Diagnostics
Drug Discovery
Personalized Medicine
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
Merck
Quest Diagnostics
Abbott
Roche
Illumina
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Cisbio Bioassays
Athena Diagnostics
BGI
Wuxi APP
Aepodia
Proteome Sciences
Genewiz
Key Questions Addressed in this Report
What is the 10-year outlook for the global Neurological Biomarkers market?
What factors are driving Neurological Biomarkers market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurological Biomarkers market opportunities vary by end market size?
How does Neurological Biomarkers break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neurological Biomarkers Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Neurological Biomarkers by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Neurological Biomarkers by Country/Region, 2019, 2023 & 2030
2.2 Neurological Biomarkers Segment by Type
2.2.1 Proteomics
2.2.2 Genomics
2.2.3 Imaging
2.2.4 Bioinformatics
2.2.5 Others
2.3 Neurological Biomarkers Sales by Type
2.3.1 Global Neurological Biomarkers Sales Market Share by Type (2019-2024)
2.3.2 Global Neurological Biomarkers Revenue and Market Share by Type (2019-2024)
2.3.3 Global Neurological Biomarkers Sale Price by Type (2019-2024)
2.4 Neurological Biomarkers Segment by Application
2.4.1 Diagnostics
2.4.2 Drug Discovery
2.4.3 Personalized Medicine
2.4.4 Others
2.5 Neurological Biomarkers Sales by Application
2.5.1 Global Neurological Biomarkers Sale Market Share by Application (2019-2024)
2.5.2 Global Neurological Biomarkers Revenue and Market Share by Application (2019-2024)
2.5.3 Global Neurological Biomarkers Sale Price by Application (2019-2024)
3 Global Neurological Biomarkers by Company
3.1 Global Neurological Biomarkers Breakdown Data by Company
3.1.1 Global Neurological Biomarkers Annual Sales by Company (2019-2024)
3.1.2 Global Neurological Biomarkers Sales Market Share by Company (2019-2024)
3.2 Global Neurological Biomarkers Annual Revenue by Company (2019-2024)
3.2.1 Global Neurological Biomarkers Revenue by Company (2019-2024)
3.2.2 Global Neurological Biomarkers Revenue Market Share by Company (2019-2024)
3.3 Global Neurological Biomarkers Sale Price by Company
3.4 Key Manufacturers Neurological Biomarkers Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurological Biomarkers Product Location Distribution
3.4.2 Players Neurological Biomarkers Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Neurological Biomarkers by Geographic Region
4.1 World Historic Neurological Biomarkers Market Size by Geographic Region (2019-2024)
4.1.1 Global Neurological Biomarkers Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Neurological Biomarkers Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Neurological Biomarkers Market Size by Country/Region (2019-2024)
4.2.1 Global Neurological Biomarkers Annual Sales by Country/Region (2019-2024)
4.2.2 Global Neurological Biomarkers Annual Revenue by Country/Region (2019-2024)
4.3 Americas Neurological Biomarkers Sales Growth
4.4 APAC Neurological Biomarkers Sales Growth
4.5 Europe Neurological Biomarkers Sales Growth
4.6 Middle East & Africa Neurological Biomarkers Sales Growth
5 Americas
5.1 Americas Neurological Biomarkers Sales by Country
5.1.1 Americas Neurological Biomarkers Sales by Country (2019-2024)
5.1.2 Americas Neurological Biomarkers Revenue by Country (2019-2024)
5.2 Americas Neurological Biomarkers Sales by Type
5.3 Americas Neurological Biomarkers Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurological Biomarkers Sales by Region
6.1.1 APAC Neurological Biomarkers Sales by Region (2019-2024)
6.1.2 APAC Neurological Biomarkers Revenue by Region (2019-2024)
6.2 APAC Neurological Biomarkers Sales by Type
6.3 APAC Neurological Biomarkers Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Neurological Biomarkers by Country
7.1.1 Europe Neurological Biomarkers Sales by Country (2019-2024)
7.1.2 Europe Neurological Biomarkers Revenue by Country (2019-2024)
7.2 Europe Neurological Biomarkers Sales by Type
7.3 Europe Neurological Biomarkers Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neurological Biomarkers by Country
8.1.1 Middle East & Africa Neurological Biomarkers Sales by Country (2019-2024)
8.1.2 Middle East & Africa Neurological Biomarkers Revenue by Country (2019-2024)
8.2 Middle East & Africa Neurological Biomarkers Sales by Type
8.3 Middle East & Africa Neurological Biomarkers Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurological Biomarkers
10.3 Manufacturing Process Analysis of Neurological Biomarkers
10.4 Industry Chain Structure of Neurological Biomarkers
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurological Biomarkers Distributors
11.3 Neurological Biomarkers Customer
12 World Forecast Review for Neurological Biomarkers by Geographic Region
12.1 Global Neurological Biomarkers Market Size Forecast by Region
12.1.1 Global Neurological Biomarkers Forecast by Region (2025-2030)
12.1.2 Global Neurological Biomarkers Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Neurological Biomarkers Forecast by Type
12.7 Global Neurological Biomarkers Forecast by Application
13 Key Players Analysis
13.1 Thermo Fisher Scientific
13.1.1 Thermo Fisher Scientific Company Information
13.1.2 Thermo Fisher Scientific Neurological Biomarkers Product Portfolios and Specifications
13.1.3 Thermo Fisher Scientific Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Thermo Fisher Scientific Main Business Overview
13.1.5 Thermo Fisher Scientific Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Neurological Biomarkers Product Portfolios and Specifications
13.2.3 Merck Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Quest Diagnostics
13.3.1 Quest Diagnostics Company Information
13.3.2 Quest Diagnostics Neurological Biomarkers Product Portfolios and Specifications
13.3.3 Quest Diagnostics Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Quest Diagnostics Main Business Overview
13.3.5 Quest Diagnostics Latest Developments
13.4 Abbott
13.4.1 Abbott Company Information
13.4.2 Abbott Neurological Biomarkers Product Portfolios and Specifications
13.4.3 Abbott Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Abbott Main Business Overview
13.4.5 Abbott Latest Developments
13.5 Roche
13.5.1 Roche Company Information
13.5.2 Roche Neurological Biomarkers Product Portfolios and Specifications
13.5.3 Roche Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Roche Main Business Overview
13.5.5 Roche Latest Developments
13.6 Illumina
13.6.1 Illumina Company Information
13.6.2 Illumina Neurological Biomarkers Product Portfolios and Specifications
13.6.3 Illumina Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Illumina Main Business Overview
13.6.5 Illumina Latest Developments
13.7 Bio-Rad Laboratories
13.7.1 Bio-Rad Laboratories Company Information
13.7.2 Bio-Rad Laboratories Neurological Biomarkers Product Portfolios and Specifications
13.7.3 Bio-Rad Laboratories Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Bio-Rad Laboratories Main Business Overview
13.7.5 Bio-Rad Laboratories Latest Developments
13.8 QIAGEN
13.8.1 QIAGEN Company Information
13.8.2 QIAGEN Neurological Biomarkers Product Portfolios and Specifications
13.8.3 QIAGEN Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 QIAGEN Main Business Overview
13.8.5 QIAGEN Latest Developments
13.9 Myriad RBM
13.9.1 Myriad RBM Company Information
13.9.2 Myriad RBM Neurological Biomarkers Product Portfolios and Specifications
13.9.3 Myriad RBM Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Myriad RBM Main Business Overview
13.9.5 Myriad RBM Latest Developments
13.10 Cisbio Bioassays
13.10.1 Cisbio Bioassays Company Information
13.10.2 Cisbio Bioassays Neurological Biomarkers Product Portfolios and Specifications
13.10.3 Cisbio Bioassays Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Cisbio Bioassays Main Business Overview
13.10.5 Cisbio Bioassays Latest Developments
13.11 Athena Diagnostics
13.11.1 Athena Diagnostics Company Information
13.11.2 Athena Diagnostics Neurological Biomarkers Product Portfolios and Specifications
13.11.3 Athena Diagnostics Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Athena Diagnostics Main Business Overview
13.11.5 Athena Diagnostics Latest Developments
13.12 BGI
13.12.1 BGI Company Information
13.12.2 BGI Neurological Biomarkers Product Portfolios and Specifications
13.12.3 BGI Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 BGI Main Business Overview
13.12.5 BGI Latest Developments
13.13 Wuxi APP
13.13.1 Wuxi APP Company Information
13.13.2 Wuxi APP Neurological Biomarkers Product Portfolios and Specifications
13.13.3 Wuxi APP Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Wuxi APP Main Business Overview
13.13.5 Wuxi APP Latest Developments
13.14 Aepodia
13.14.1 Aepodia Company Information
13.14.2 Aepodia Neurological Biomarkers Product Portfolios and Specifications
13.14.3 Aepodia Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Aepodia Main Business Overview
13.14.5 Aepodia Latest Developments
13.15 Proteome Sciences
13.15.1 Proteome Sciences Company Information
13.15.2 Proteome Sciences Neurological Biomarkers Product Portfolios and Specifications
13.15.3 Proteome Sciences Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Proteome Sciences Main Business Overview
13.15.5 Proteome Sciences Latest Developments
13.16 Genewiz
13.16.1 Genewiz Company Information
13.16.2 Genewiz Neurological Biomarkers Product Portfolios and Specifications
13.16.3 Genewiz Neurological Biomarkers Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Genewiz Main Business Overview
13.16.5 Genewiz Latest Developments
14 Research Findings and Conclusion